Abstract Introduction Although breast cancers expressing estrogen receptor-α (ERα) and progesterone receptors (PR) are the most common form of mammary malignancy in humans, it has been difficult to develop a suitable mouse model showing similar steroid hormone responsiveness. STAT transcription factors play critical roles in mammary gland tumorigenesis, but the precise role of STAT1 remains unclear. Herein, we show that a subset of human breast cancers display reduced STAT1 expression and that mice lacking STAT1 surprisingly develop ERα+/PR+ mammary tumors. Methods We used a combination of approaches, including histological examination, gene targeted mice, gene expression analysis, tumor transplantaion, and immunophenotyping, to pursue this...
Mutation and loss of function in p53 are common features among human breast cancers. Here we use BAL...
Mutation and loss of function in p53 are common features among human breast cancers. Here we use BAL...
Oestrogen receptor-positive (ER+) breast cancer accounts for over three quarters of all diagnosed br...
STAT1-deficient mice spontaneously develop estrogen receptor a-positive luminal mammary carcinoma
Female 129:Stat1-null mice (129S6/SvEvTac-Stat1(tm1Rds) homozygous) uniquely develop estrogen-recept...
<div><p>Female 129:<i>Stat1-null</i> mice (129S6/SvEvTac-<i>Stat1<sup>tm1Rds</sup></i> homozygous) u...
Abstract Background Stat1 gene-targeted knockout mice (129S6/SvEvTac-Stat1 tm1Rds) develop estrogen ...
SummaryEstrogen receptor alpha-positive (ERα+) luminal tumors are the most frequent subtype of breas...
Estrogen receptor alpha-positive (ERα+) luminal tumors are the most frequent subtype of breast cance...
Approximately 70 % of human breast cancers are estrogen receptor! (ER!)-positive, but the origins of...
BackgroundStat1 gene-targeted knockout mice (129S6/SvEvTac-Stat1 tm1Rds) develop estrogen receptor-p...
Approximately 75% of all breast cancers express the nuclear hormone receptor estrogen receptor α (ER...
Signaling through the prolactin receptor (PrlR) has been associated with human ERa+ breast cancer th...
Androgen receptor (AR) is commonly expressed in both the epithelium of normal mammary glands and in ...
Breast cancer (BC) is primarily triggered by estrogens, especially 17β-estradiol (E2), which are syn...
Mutation and loss of function in p53 are common features among human breast cancers. Here we use BAL...
Mutation and loss of function in p53 are common features among human breast cancers. Here we use BAL...
Oestrogen receptor-positive (ER+) breast cancer accounts for over three quarters of all diagnosed br...
STAT1-deficient mice spontaneously develop estrogen receptor a-positive luminal mammary carcinoma
Female 129:Stat1-null mice (129S6/SvEvTac-Stat1(tm1Rds) homozygous) uniquely develop estrogen-recept...
<div><p>Female 129:<i>Stat1-null</i> mice (129S6/SvEvTac-<i>Stat1<sup>tm1Rds</sup></i> homozygous) u...
Abstract Background Stat1 gene-targeted knockout mice (129S6/SvEvTac-Stat1 tm1Rds) develop estrogen ...
SummaryEstrogen receptor alpha-positive (ERα+) luminal tumors are the most frequent subtype of breas...
Estrogen receptor alpha-positive (ERα+) luminal tumors are the most frequent subtype of breast cance...
Approximately 70 % of human breast cancers are estrogen receptor! (ER!)-positive, but the origins of...
BackgroundStat1 gene-targeted knockout mice (129S6/SvEvTac-Stat1 tm1Rds) develop estrogen receptor-p...
Approximately 75% of all breast cancers express the nuclear hormone receptor estrogen receptor α (ER...
Signaling through the prolactin receptor (PrlR) has been associated with human ERa+ breast cancer th...
Androgen receptor (AR) is commonly expressed in both the epithelium of normal mammary glands and in ...
Breast cancer (BC) is primarily triggered by estrogens, especially 17β-estradiol (E2), which are syn...
Mutation and loss of function in p53 are common features among human breast cancers. Here we use BAL...
Mutation and loss of function in p53 are common features among human breast cancers. Here we use BAL...
Oestrogen receptor-positive (ER+) breast cancer accounts for over three quarters of all diagnosed br...